Clinical trials: Hepatitis B, completed
Chronic HBV Infection
Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection
The primary objective of this study is to compare the safety and efficacy of HS-10234 versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with chronic hepatitis B virus (HBV) infection.
- Trial name
- NCT03903796
- Testing
- HS-10234, TDF
- Where
- China
- Volunteers
- 963 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Hepatitis B
To Evaluate Immunogenicity & Safety of GSK Bio's DTPa-HBV-IPV/Hib (Mixed Vaccine) and DTPa-IPV/Hib + HBV Vaccines
This study assessed the immunogenicity and safety of two vaccination regimens that employed either GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine or DTPa-IPV/Hib vaccine.
- Trial name
- NCT00366366
- Testing
- Infanrix-Hexa
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Parathyroid Hormone, Tenofovir Disoproxil Fumarate
The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With TDF
Nucleot(s)ide is an antiviral drug that can reduce the number of viruses, reduce the risk of HCC, regress hepatic fibrosis and reduce death from Hepatitis B viral infection.
- Conditions
- Parathyroid Hormone, Tenofovir Disoproxil Fumarate, Chronic Hepatitis B Virus, Vitamin D
- Trial name
- TDF (NCT05313477)
- Testing
- Ergocalciferol Capsules, Calcium carbonate
- Where
- Thailand
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Chronic Hepatitis B
TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA
This study will provide a rationale for switch from lamivudine plus adefovir to tenofovir monotherapy in Lamivudine plus Adefovir Treated Lamivudine-resistant chronic hepatitis B patients with Undetectable Hepatitis B Virus DNA
- Trial name
- NCT01732367
- Testing
- Lamivudine plus adefovir, Tenofovir
- Where
- South Korea
- Volunteers
- 171 people
- Sponsor
- Keimyung University Dongsan Medical Center
Chronic Hepatitis B
CHARM: Chronic Hepatitis B Antihepadnaviral Resistance Mutation Study
This study has the aim of describing viral mutation profiles in patients diagnosed with chronic hepatitis B receiving antihepadnaviral therapy.
- Trial name
- CHARM (NCT00645736)
- Testing
- No intervention
- Where
- Australia
- Volunteers
- 788 people
- Sponsor
- Gilead Sciences
Hepatitis b
The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines
This study is an expanded Phase 2/Phase 3 clinical trial base on the safety data obtained from the phase 1 clinical trial. The purpose of this study is to further evaluate the immunogenicity and safety of 60mcg/30mcg recombinant…
- Trial name
- NCT01203319
- Testing
- 60mcg/1.0ml recombinant hepatitis B vaccine, 30mcg/1.0ml recombinant hepatitis B vaccine, 10mcg/1.0ml recombinant hepatitis B vaccine
- Volunteers
- 1,091 people
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Hepatitis C, Hepatitis B
HBV/HCV/HIV in Belgian Prisons
To assess the prevalence of blood-borne viral infections in prisons in Belgium, screening will be executed in several prisons in Flanders, Brussels and Wallonia to obtain a geographical representative distribution.
- Conditions
- Hepatitis C, Hepatitis B, HIV Infections
- Trial name
- NCT04366492
- Testing
- Prevalence of blood borne viral infections (HBV/HCV/HIV)
- Where
- 2 sites in Belgium
- Volunteers
- 3,045 people, healthy volunteers welcome
- Sponsor
- Hasselt University
Hepatitis B, Chronic
Long-Term Lamivudine Therapy for Chronic Hepatitis B
This study will evaluate the long-term safety and effectiveness of lamivudine therapy and the possibility of stopping therapy in patients whose hepatitis B is chronic, that is, long lasting, and which has responded to treatment.
- Trial name
- NCT00120354
- Testing
- Blood Testing, Percutaneous Liver Biopsy, Lamivudine Therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non Hodgkin's Lymphoma, Hepatitis B
Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B
Hepatitis B (HBV) reactivation and hepatitis flare induced by cytotoxic chemotherapy is common in cancer patients who have chronic HBV infection.
- Trial name
- HBVNHL (NCT00926757)
- Testing
- Entecavir prophylaxis, Therapeutic entecavir
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Hepatitis B, Chronic
To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)
This study is to evaluate the antiviral efficacy of add-on adefovir to telbivudine in non-responders to telbivudine monotherapy after 24 and 36 initial weeks.
- Trial name
- NCT00537537
- Testing
- Telbivudine
- Where
- 3 sites in India
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
The Safety and Immunogenicity of DTP/Hepatitis B 10ug Hib Vaccine (Bio Farma)
The objective of this study was to know the safety of DTP/Hepatitis B and Hib/PRP-T vaccine and immediate reactions within the first 30 minutes after injection.
- Trial name
- NCT01977196
- Testing
- DPT/HepatitisB/Hib vaccine
- Where
- Indonesia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Chronic Hepatitis B
Study to Compare the Safety and Pharmacokinetics of CKD-390 Tablet With Viread® Tablet
The purpose of this study is to compare the safety and pharmacokinetics of CKD-390(Tenofovir Disoproxil Aspartate) and Viread® tablet(Tenofovir Disoproxil Fumarate) in healthy male volunteers.
- Trial name
- NCT02589457
- Testing
- CKD-390, Viread® tablet
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hepatitis B, Chronic
A Two-year Study of Telbivudine in HBeAg Negative Hepatitis
Based on GLOBE study supplying predictability analysis results, ROADMAP strategy provides an individualized telbivudine treatment roadmap strategy designed to achieve optimal viral suppression and low resistance rate in patients…
- Trial name
- STEN (NCT01521975)
- Testing
- Telbivudine, Adefovir dipivoxil
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Metabolic Associated Fatty Liver Disease, Pancreatic Steatosis
Metabolic Associated Fatty Liver Disease and Pancreatic Steatosis in Obese Versus Lean Chronic Hepatitis B Patients
This study aimed to evaluate the prevalence of metabolic associated fatty liver disease (MAFLD), fatty pancreas and hepatic fibrosis in obese and lean patients with chronic hepatitis B; either treatment naive or on treatment with…
- Conditions
- Metabolic Associated Fatty Liver Disease, Pancreatic Steatosis, Obese, Lean
- Trial name
- NCT07175688
- Testing
- Abdominal Ultrasound, Transient elastography, Waist Circumference
- Where
- Egypt
- Volunteers
- 217 people
- Sponsor
- Tanta University
HCV Infection, HIV Infections
Addressing the Cascade of Care in Vulnerable Populations With Poor Access to Healthcare in Madrid
Data on the prevalence of hepatitis C virus (HCV) for other vulnerable groups in Madrid, such as homeless persons and migrants, are scarce, and it is now necessary to implement intervention and elimination plans.
- Conditions
- HCV Infection, HIV Infections, Drug Use, HBV (Hepatitis B Virus)
- Trial name
- (UMC) (NCT04062253)
- Testing
- HCV rapid test
- Where
- Spain
- Volunteers
- 2,001 people, healthy volunteers welcome
- Sponsor
- Hospital Universitario Infanta Leonor
Hiv, Hepatitis B
Delivering a Multi-disease Screening Tool to Migrant Populations
Migrants' overall health status may be improved by increasing the detection of certain infectious diseases and other conditions for which effective care is available.
- Conditions
- Hiv, Hepatitis B, Hepatitis C, Tuberculosis
- Trial name
- ISMiHealth (NCT05868005)
- Testing
- Clinical decision support system for screening of migrants using the ISMiHealth software tool.
- Where
- 2 sites in Spain
- Volunteers
- 980 people, healthy volunteers welcome
- Sponsor
- Barcelona Institute for Global Health
Hepatitis B, Chronic
A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue
This Phase 4 study is designed for the collection of blood biomarker samples from participants who have completed CHB treatment with at least 24 weeks of a pegylated interferon alfa-2a (Peg-IFN alfa-2a) containing regimen and at…
- Trial name
- NCT01855997
- Testing
- Peg-IFN alfa-2a
- Where
- 84 sites in Austria, Bulgaria and 13 more
- Volunteers
- 1,669 people
- Sponsor
- Hoffmann-La Roche
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
This will be a Phase II study investigating single agent pembrolizumab (Keytruda®) as a second-line therapy for subjects with hepatocellular carcinoma (HCC) who either progressed on or after sorafenib or did not tolerate…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatitis C Infection, Refractory Liver Carcinoma
- Trial name
- NCT02940496
- Testing
- Elbasvir/Grazoprevir, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatitis B Virus Infection
Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)
To describe the immunogenicity and safety of modified process hepatitis B vaccine administered to renal predialysis and dialysis patients
- Trial name
- NCT00440297
- Testing
- Comparator: modified process hepatitis B vaccine, Comparator: ENGERIX-B™
- Volunteers
- 277 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis B
Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B
This study is a multi-center, randomized, open-label and positive controlled Phase II Clinical trial to assess efficacy and safety of Ypeginterferon alfa-2b, once a week, in 3 dose-groups: 90mcg, 135mcg and 180mcg, respectively…
- Trial name
- NCT01143662
- Testing
- Ypeginterferon alfa-2b, Peginterferon alfa-2a
- Where
- 39 sites in China
- Volunteers
- 205 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.